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Abstract  1 
Background 2 
Extensively hydrolysed formulas (EHFs) and amino acid formulas (AAFs) with proven 3 
hypoallergenicity are used for children suffering from cow’s milk allergy, when breast milk is not 4 
available. However, these feeds are often used in other medical conditions where tolerance and 5 
absorption of whole protein is affected, frequently without assessment of efficacy. This practice 6 
survey assessed the use of these feeds in paediatric conditions other than CMA; aiming to describe 7 
the population, growth parameters and micronutrient status.  8 
 9 
Methodology 10 
Four National Health Service tertiary paediatric centres participated in this practice survey.  11 
Inclusion: children between 0-18 years, consuming >25% of their estimated energy requirements of 12 
an EHF/AAF for any condition other than allergic disease. Anonymised data was collected: (i) 13 
descriptive information (ii) indications (iii) type and route of feeding (iv) growth status and 14 
nutritional deficiencies (v) medication and vitamin and mineral supplementation.  15 
 16 
Results  17 
One hundred-and-ninety-one children were included with a median age of 19 months [IQR: 4 to 63]. 18 
Seventeen percent (33/191) were on AAFs and 83% (158/191) on EHFs. The feeds were commonly 19 
used in cancer 26% and critical illness 31%.  The majority (73%) of children had enteral feeds via a 20 
nasogastric tube. Nutritional biomarkers were performed in 29% of children and 83% were on a 21 
vitamin or mineral supplement.  22 
 23 
Conclusions 24 
This practice survey found that EHFs and AAFs were used in a variety of medical conditions.  25 
Indications for feed choice varied, and evidence-based research supporting the use was scarce. 26 
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Breast milk represents the optimal source of nutrition for all infants, including those with medical 4 
conditions.(1)  However, for certain conditions, when breast milk is not available or insufficient, 5 
specialist feeds may be recommended, which include extensively hydrolysed formulas (EHFs) and 6 
amino acid formulas (AAFs).(2) When these feeds are intended for the management of cow’s milk 7 
allergy (CMA) they have to be assessed according to the criteria by the European Academy for 8 
Allergy and Clinical Immunology [EAACI](3, 4)and the American Academy of Paediatrics [AAP] (5) to 9 
be tolerated by 90% of children at a 95% CI with a challenge proven CMA. In addition manufacturers  10 
need to also demonstrate safety and efficacy  with regards to normal physical growth in infants.(6)  11 
However, due to the characteristics of EHF and AAF, including  peptides, amino-acids, glucose 12 
polymers and varying levels of medium chain and long chain fatty acids, they are also commonly 13 
used in the nutritional support of a variety of acute and chronic childhood illnesses affecting the 14 
gastrointestinal tract and are chosen to manage symptoms of gastrointestinal dysmotility,(7, 8) 15 
malabsorption,(9-11) drug induced mucositis (12) and feed intolerance,(13) using a wide variety of 16 
definitions to characterise an intolerance to a standard feed.(14) The evidence to recommend the 17 
use of  AAFs and EHFs in many of these conditions is limited,(14-16) in addition to lack of defined 18 
criteria for the assessment and monitoring of tolerance, efficacy or adequacy. Nutritional 19 
requirements differ depending on the clinical diagnosis for both macro and micronutrients, 20 
complicated further by the feeding route (i.e. nasogastric) and polypharmacy.(14) This survey was 21 
therefore aimed at describing current clinical practice, including when, how and for whom these 22 
feeds were used, to better inform future research and guidelines on use of AAFs and EHFs beyond 23 




In the United Kingdom (UK) 20 tertiary National Health Service centres are responsible for the 28 
majority of complex paediatric patients. In order to include a wide range of diagnostic categories, a 29 
spread across the UK was considered desirable, so for this practice survey a convenience sample of 30 
eight centres with specialist paediatric dietitians was selected, of which four agreed to participate. 31 
These were University Hospital Southampton Hospital NHS Foundation Trust, University Hospitals 32 
Bristol NHS Foundation Trust, Royal Alexandra Children’s Hospital, Brighton University Hospital NHS 33 
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Trust and King’s College Hospital NHS Foundation Trust in London. These centres provide specialist 1 
regional services to a variety of children with complex diseases including, children with congenital 2 
heart disease requiring surgery, critically ill children, infants with gastrointestinal disorders including 3 
congenital or acquired intestinal failure, and those with neurodisabilities, cholestatic liver disease 4 
and various cancers.  5 
NHS Health Research Authority waived the need for consent as this was classified as a practice 6 
survey. An anonymised excel spreadsheet (Version 2016) was developed by the lead researcher and 7 
statistician, and circulated to the four centres with iterative changes until all centres agreed on both 8 
the survey data collection sheet and information required.  Data was collected from February to 9 
October 2018. For this survey, no patient identifiable information was collected and no additional 10 
tests, interventions or information was required outside of what was recorded in medical notes at 11 
routine clinic appointments or during hospital stays. Data collection was designed to capture 12 
information in the following domains: (i) descriptive information on children prescribed EHFs/AAFs 13 
(ii) indications for use of EHFs/AAFs (iii) type of feed including feed concentration and route of 14 
feeding (e.g. oral, nasogastric) (iv) growth status, (v) nutritional deficiencies as measured by 15 
biomarkers and (vi) medications and vitamin and mineral supplementation.  Due to the similarities in 16 
protein hydrolysis, glucose polymer and lipid content of semi-elemental and extensively hydrolysed 17 
feeds for the purpose of this study all semi elemental feeds, as long as they were extensively 18 
hydrolysed, were grouped under EHFs and all elemental feeds under AAFs (Table 1). EHFs and AAFs 19 
included did not required hypoallergenicity testing for suitability for the management of CMA as this 20 
survey excluded patients with a CMA.  21 
 22 
The following inclusion and exclusion criteria were used:  23 
Inclusion criteria: 24 
1. Children between 0-18 years consuming an extensively hydrolysed formula (EHF) (17) or amino acid 25 
formula (AAF) as part of their enteral nutrition (including oral and/or tube feeding) providing >25% 26 
of estimated energy requirements for any condition other than allergic disease  27 
 28 
Exclusion criteria  29 
1. Children with confirmed IgE or non-IgE mediated CMA or multiple food allergies which resulted in 30 
the prescription of  EHFs or AAFs  31 
2. Children on an elimination diet to confirm suspected non-IgE mediated CMA or multiple food allergy 32 
3. Confirmed (by endoscopy with biopsy) eosinophilic gastrointestinal disease (EGID) 33 
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Dietitians from survey centres received a protocol to reflect the survey spreadsheet, with further 1 
details on data collection and also describing parameters in more detail to reduce data collection 2 
bias (Table 1).   3 
 4 
Statistical Analysis 5 
Statistical analysis was performed using R version 3.4.4 (R Foundation for Statistical Computing, 6 
Vienna, Austria). Continuous variables are presented as medians with interquartile ranges and 7 
categorical variables as frequencies and percentages.  The Mann-Whitney U test was used to 8 
examine the differences in z-scores between groups including: AAF vs EHF, gender, time on formula 9 
(</> 3 months), medications and symptoms. Pearson’s chi square test with continuity corrections or 10 
Fisher’s Exact test were used, where appropriate, to compare rates of children in 11 
outpatient/inpatient setting, rates of improved growth, assess vitamin/mineral deficiencies and 12 
vitamin/mineral supplementation between children on either EHFs or AAFs.  13 
 14 
Multiple logistic regression was used to investigate the probability of being prescribed an AAF versus 15 
EHF based on diagnoses/symptoms, prematurity, time on the feed, anthropometric measures with 16 
adjustment for potential confounders of age and gender. Only variables that had a statistically 17 
significant impact are reported in this study. All tests were two-tailed and significance level was set 18 
to 0.05. 19 
 20 
The WHO Anthro (< 5 years of age) and Anthro Plus (> 5 years of age) software was used to convert 21 
growth parameters into z-scores and malnutrition was expressed as per WHO definitions (Table 22 
2).(18) For ex-preterm infants z-scores were corrected using the Fenton growth charts for preterm 23 




One hundred-and-ninety-one children from the four centres (Table 3) were included: 71% (136/191) 28 
inpatients and 29% (55/191) outpatients. Fifty five percent (106/191) were male and 21% of children 29 
(40/191) were born preterm (< 37 weeks gestational age). The median age at the time of data 30 
collected was 19 months [IQR: 4 to 63] and median gestational age of ex-preterm infants at birth 31 
was 30 weeks gestational age [IQR: 26 to 33.1]. With regards to prescribed feeds, 17% (33/191) were 32 
on an AAF and 83% (158/191) on an EHF. Most of the children on an EHF in this practice survey [36% 33 
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(57/158)] were critically ill on a PICU, where half of children were admitted following planned 1 
cardiac surgery for congenital heart disease or as a result of acute admission for respiratory failure. 2 
The standard practice of this PICU (University Hospital Southampton Hospital NHS Foundation Trust) 3 
was to provide nutrient-energy dense whey based EHFs to all infants/ children on admission.(20) The 4 
second most common reason for use of EHFs was a diagnosis of cancer [25% (39/158)], including 5 
neuroblastoma, osteosarcoma, rhabdomyosarcoma and acute myeloid leukaemia) (Table 4).  6 
 7 
This practice survey found no significant difference (p = 0.99) in the proportion of prescribed AAFs 8 
for an inpatient 17.6% (24/136) or outpatient 16.4% (9/55). In 95% of cases, feeds were 9 
reconstituted according to manufacturer recommendations. Only 5% (9/191) of cases had the feed 10 
reconstituted at a higher concentration and 1% (1/191) at a lower concentration. In 60% (114/191) 11 
of the population surveyed, EHFs and AAFs contributed > 75% of energy requirements (Figure 1). 12 
Seventy three percent of patients (139/191) received nasogastric tube feeds and 14% had a 13 
percutaneous gastrostomy (Table 5). In addition, 10% (20/191) of feeds were used to supplement an 14 
oral diet, the majority of which were on EHFs [80% (16/20)]. In 11% (21/191) of cases, these feeds 15 
were used (via a variety of enteral routes) to supplement parenteral nutrition, of which 52% 16 
[(11/21)] were prescribed an AAF.  17 
Most children were on either EHF or AAF for 1-4 weeks (37%). However, in 29% and 7% of recruited 18 
patients these feeds were used for 3-12 months and > 12 months respectively. A heat map stratified 19 
by reason for admission and time on the feed, found that children on the PICU, where 50% of 20 
patients had a planned admission for cardiac surgery, were on the feed for 1-4 weeks and those 21 
remaining on these feeds for a longer period of time (3-12 months) were those with cancer and 22 
gastrointestinal diseases (Figure 2).  23 
 24 
Indications for using an EHF and AAF 25 
When assessing the indications for using an EHF or AAF, 32% responded that the use of these feeds 26 
was part of their standard practice protocol in their unit and 29% used these feeds when children 27 
were deemed not to tolerate standard whole protein paediatric feeds, due to vomiting 12%, 28 
congenital/acquired gastrointestinal pathology 7%, malabsorption 5%, diarrhoea 3%, reflux 1% and 29 
constipation 1%.  In addition, 10% marked “other” reasons for using an EHF or AAF. Figure 3, 30 
summarises the combined indications for AAF and EHF into a heat map (Figure 3).  Outside of PICU, 31 
these feeds were more commonly used in cancer and gastrointestinal diseases, including 32 
congenital/acquired gastrointestinal pathology, in addition to children with liver disease. 33 
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Variables that significantly increased the likelihood of children being on either EHFs or AAFs were 1 
assessed using multiple logistic regression analysis and results are reported as percentage 2 
probability in Table 6.  Diarrhoea, vomiting or malabsorption as a single variable increased the use of 3 
an EHF, but in combination and increased numbers, in particular in association with male gender, 4 
the higher the probability of using an AAF.  5 
Nutritional Status  6 
The median weight-for-age z-score (21) (21) for the population was -1.2 [IQR:-2.1 to -0.1], height-for-7 
age z-score (HAZ) -1.3 [IQR: -2.7 to 0] and weight-for-length/height (WHZ) z-score was -0.2 [IQR:-1-1 8 
to 0.8]. Moderate malnutrition, as defined by a z-score <-2 z scores,(18) was present in 29.8% for 9 
WAZ (underweight), 10.7% for WHZ (wasted), and 36.4% for HAZ (stunted). When malnourished 10 
children were stratified by diagnosis, we found that children with cardiac disorders and ex-preterm 11 
infants both in PICU as well as on the wards particularly had poor growth parameters as highlighted 12 
in Table 7.  13 
No statistical difference was found in WAZ (p = 0.97), HAZ (p = 0.54) and WAZ (p=0.51) between 14 
children on an EHF versus an AAF.  However, children who were on these feeds (EHF or AAF) for >3 15 
months (compared to < 3 months) had an improved WHZ z-score: 0.0 [IQR:-0.5 to 0.9] vs. -0.3 [IQR:-16 
1.4 to 0.6], (p=0.02).  The presence of reflux (p=0.04) and malabsorption (p=0.003) had a statistically 17 
significant negative impact on WAZ and HAZ respectively.  18 
 19 
Vitamins, minerals and medications 20 
From the patients surveyed, 83% (159/191) were on either a single vitamin/mineral supplement or a 21 
multivitamin and mineral supplement (Table 8). However, only 29% (55/191) of children vitamin and 22 
mineral status was assessed during the study period.  These assessments were more commonly 23 
performed in children on an AAF [45% (15/33)] than an EHF [25% (40/158)]. Low vitamin D status 24 
was most frequently documented (5%), followed by zinc, vitamin A and phosphate each at 3%. 25 
Numbers were too small to perform further statistical analysis to assess any association of vitamin 26 
and mineral deficiencies on either EHF/AAF.    27 
In this practice survey, 30.4% (58/191) were prescribed one medication, 29.8% (57/191) two and 28 
21% (41/191) three or more medications.  Forty percent of children (77/191) were prescribed a 29 
proton pump inhibitor (PPI), followed by anti-emetics [30% (58/191)] and diuretics [28% (53/191)] 30 
(Table 8). The only medication that had an impact on growth was PPI use, which was negative for 31 
both WAZ (p=0.02) and HAZ (p=0.001). 32 
 33 
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Discussion 1 
This practice survey, set out to describe the use of EHFs and AAFs in children with various diagnoses 2 
to establish when, how and for whom these feeds were used. We found that 83% of children were 3 
prescribed an EHF and only 17% an AAF, also reflective of practice for CMA, where AAF is reserved 4 
for the more severe cases.(22) The most common diagnostic category where these feeds were used 5 
were in critically ill children, followed by cancer and gastrointestinal diseases. A higher percentage 6 
(39%) of children with gastrointestinal diagnoses (which included congenital gastrointestinal 7 
pathology) were on an AAF, followed by children with cancer diagnoses, prematurity and liver 8 
disease. Children on PICU tended to stay on either of these feeds for less than 4 weeks, but those 9 
with cancer, gastrointestinal diseases and congenital cardiac disorders remained on either EHF or 10 
AAF for a longer period of time. This reflects the nature of the diagnosis and course of disease.  11 
 12 
The most common clinical motivation for using either EHFs or AAFs in conditions other than CMA, is 13 
to improve perceived feed intolerance, which may include vomiting, raised gastric residual volumes, 14 
abdominal distention, diarrhoea and constipation.(14) Our findings indicate that poor tolerance of  15 
standard feeds, reflected by vomiting and diarrhoea are common reasons for choosing an EHF or 16 
AAF, when not using these feeds as standard practice. Although feeding intolerance is well 17 
documented in many paediatric diagnoses,(8, 23-25) quantifying the severity or frequency of 18 
intolerance that requires a feed change is ambiguous and varies between centres and diagnoses.  In 19 
our practice survey, an energy-dense whey-based EHF was used by one centre as routine practice in 20 
their young critically ill children. Marino et al (20) showed lower incidence of feed intolerance, such 21 
as vomiting, high gastric residual volumes and diarrhoea in critically ill children, whilst meeting 22 
prescribed energy requirements when using these feeds. This participating centre, admitted 50% of 23 
children for planned cardiac surgery. Dysmotility is not only well documented in children with this 24 
diagnosis,(26) but in critically ill children per se.(23) Nutritional characteristics of the EHF, including 25 
the type of protein, the extent of hydrolysis, the osmolality and fat content, pre and probiotics may 26 
have all contributed to this positive finding.  27 
Children with cancer commonly have gastrointestinal symptoms including diarrhoea, abdominal pain 28 
and vomiting related to both the treatment, as well as the the underlying diagnosis.(12) The 29 
evidence for either EHF or AAF to alleviate these symptoms to improve delivery of nutrients is 30 
limited and mainly consensus based.(12) Chemotherapy frequently induces intestinal mucositis, with 31 
morphological changes including the flattening of the villi, villus atrophy and  down-regulation of the 32 
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enterocyte- specific gene expression that is crucial for degradation and absorption of nutrients.(27)  1 
The inflammation of the gastrointestinal tract can impact on the brush border, impacting both on 2 
the absorption of protein as well as sugars.(28) There may therefore be a role for using either 3 
EHF/AAF in paediatric cancer when gastrointestinal symptoms occur, but to date, limited clinical 4 
trials exist, supporting their routine use in this cohort.  5 
In complex gastrointestinal disorders both EHF and AAF use is commonplace. Almost 50% of our 6 
gastrointestinal cohort, were on these feeds due to not tolerating standard protein feeds and 24% 7 
had congenital gastrointestinal pathology. The use of AAF was higher in this diagnostic category, 8 
which was also highlighted by recent publications on micronutrient adequacy in children with 9 
complex gastrointestinal disease.(29, 30) In spite of its frequent use in gastrointestinal disorders 10 
including short gut syndrome, there are only a limited number of studies, often of poor quality,(31) 11 
evaluating EHFs/AAFs in a variety of gastrointestinal disease. (16, 32, 33) The motivation for use in 12 
gastrointestinal disorders is often based on the different gastric emptying kinetics of whey versus 13 
casein,(34) peptides and/or amino acids which have different absorption patterns, type of fat and 14 
lactose content. EHF/AAF are a composite of nutrients, which potentially impact on gastrointestinal 15 
tolerance, not only as a single nutrient but in combination. In addition, the heterogeneity of 16 
gastrointestinal diagnoses and medical management, makes it really difficult to establish the efficacy 17 
of these feeds.  18 
The use of EHFs for their medium chain triglyceride (MCT) content is common in children with 19 
cholestasis,(10) although there is little evidence of any beneficial effects of MCT on growth or other 20 
outcomes.(35) Unlike long chain triglycerides, the partial water solubility of MCT enables direct 21 
absorption into the portal system without the need for bile flow, which may be impaired or absent in 22 
cholestasis.(36) If liver disease progresses and children develop cirrhosis and portal hypertension the 23 
result may be intestinal changes such as mucosal oedema resulting in diarrhoea.(11) There may 24 
therefore, be a benefit to using EHFs if diarrhoea is suspected to be related to portal 25 
hypertension,(11)  however, to date there is no convincing evidence for the routine use of an EHF in 26 
liver disease. 27 
This practice survey also included children with other diagnoses. Within this category, most notably 28 
are children with neurodisabilities where dysmotility is well described.(37, 38) The current guidelines 29 
from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition on the 30 
nutritional management of children with neurodisabilities, suggest trialling whey-based feeds in 31 
10 
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children with symptoms of gastro-oesophageal reflux.(25) This suggestion followed studies by Brun 1 
et al (7, 39) and Savage et al (40)  on improved gastric emptying with whole whey protein in children 2 
with cerebral palsy.  Khoshoo et al (41) also found that energy dense partially hydrolysed whey feeds 3 
were better tolerated in this population. However, the aforementioned studies assessed tolerance 4 
for partially or whole whey protein, questioning the use of either AAF or EHF in children with 5 
neurodisabilities in particular as their macro and micronutrient requirements are often very 6 
different.  7 
Almost 10% of children in this practice survey were acutely malnourished and almost 40% had 8 
persistent malnutrition. This level of malnutrition was much higher than reported in the study by 9 
Hecht et al (42)  on European hospitalized children where 7.9% were stunted and 5% had a  BMI < -2 10 
z-score. However, this finding is in line with prevalence of malnutrition associated with chronic 11 
diseases such as congenital heart disease.(43) There was no difference in the growth parameters 12 
between AAF and EHF, but pooled data indicated that children who remained on either feed for > 3 13 
months had better WHZ. Data from this practice survey also found that more than 70% of our 14 
population received enteral tube feeding, which is usually started when oral intake does not meet 15 
nutritional requirements, in particular in the presence of malnutrition (which was common in our 16 
cohort) and during admission to PICU. We believe that this high prevalence of tube feeding in our 17 
practice survey reflects the medical complexity of children on these feeds and is similar to recently 18 
published studies on AAF use in children with complex gastrointestinal disease.(29) Furthermore, 19 
many of these children are on multiple medications, impacting on the ability to utilise and assimilate 20 
nutrients from feeds. Our survey has found a negative association between the PPI and some of the 21 
growth parameters. We cannot infer causality, however, as it is known that PPI and other 22 
medications impact on the bioavailability of nutrients essential for growth, (44,45) further work is 23 
required to understand the association between various medications and feed tolerance and 24 
growth.(44, 45)  25 
 26 
We also collected data on vitamin and mineral status, where available.  Recent publications have 27 
highlighted concerns in regards to phosphate levels in children with complex gastrointestinal 28 
conditions receiving an AAF as a sole source of nutrition.(29, 30) In only 29% of children, nutritional 29 
biomarkers for vitamin and minerals status were taken, although 36% were on these feeds for longer 30 
than three months. Current British Association for Parenteral and Enteral Nutrition (BAPEN) 31 
guidelines for tube fed patients in the UK suggest that electrolytes, B12, folate and a full blood count 32 
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are assessed until stable and after this when clinically indicated (no time interval suggested).(46) 1 
Assessment of zinc, copper and selenium levels are recommended only when clinically indicated (no 2 
time interval suggested) and vitamin D should be performed every 6 months.(46) In the light of the 3 
limited data on nutritional adequacy when using either EHF/AAF in children with complex disease, it 4 
seems prudent that children who are on these feeds for > 3 months, are monitored at least to the 5 
standard set by BAPEN.   6 
This practice survey has many limitations. The most notable is the bias introduced by the selection of 7 
the population. Only eight centres were approached from across the UK and only four of these 8 
volunteered to take part and one centre contributed more than half of the patients in this survey. 9 
We can therefore not generalise our findings to all paediatric centres in the UK nor all medical 10 
conditions where these feeds may be used. In addition, our survey does not account for the severity 11 
of disease, which varies within each category recruited for this survey and may have affected choice 12 
of feed. Although we provided definitions for diarrhoea, we did not clearly define malabsorption 13 
disorders, which may have influenced our results on indications for use of EHFs and AAFs.  As this 14 
was a survey, we also did not control for growth measurement accuracy and also the accuracy of 15 
nutritional biomarkers. Despite these limitations, this is the first survey to report the use of AAF and 16 
EHF in clinical practice and we believe, contributes useful information for future studies.  17 
 18 
Conclusion 19 
This practice survey found that EHFs and AAFs are commonly used in a variety of children with 20 
complex medical conditions, most of them receiving feeds via the enteral route. Our survey found 21 
that the primary aim of using either EHF or AAF was to improve tolerance, which may be as part of 22 
standard practice. The majority of children on these feeds are fed enterally and are on multiple 23 
medications that may impact on the bioavailability of nutrients but are not commonly monitored for 24 
vitamin and mineral status. In the light of limited evidence supporting routine use of these feeds in a 25 
variety of conditions, further research is required, on better defining composition of feeds suitable 26 
for conditions where whole protein feeds are not tolerated, including safety, indications and the 27 
cost-benefit. In the meantime, healthcare professionals need to be aware that children on either 28 
EHF/AAF with complex conditions on multiple medications should be monitored regularly to ensure 29 
adequate growth including micronutrient status. 30 
 31 
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Table 1: Feeds that were included in this survey 20 
Extensively hydrolysed (semi-elemental) feeds Amino Acid (elemental) feeds 
Nutramigen (Mead Johnson) 
Pregestimil (Mead Johnson) 
Similac Alimentum (Abbott) 
Althera (Nestle) 
Aptamil Pepti (Nutricia) 
Aptamil Pepti Junior (Nutricia) 
Infatrini Peptisorb (Nutricia) 
Neocate LCP (Nutricia) 
Neocate Junior (Nutricia) 
E028 (Nutricia) 
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Table 2: Data collected on growth and indications for feed   21 
Parameter Description  
Diagnostic category Oncology and haematology (including bone marrow transplant) 
Paediatric Intensive Care (PICU) 
Congenital heart disease –pre/peri-operatively 
Gastrointestinal disorders including: Gastroschisis, volvulus, pseudo-
obstruction, duodenal atresia, jejunal atresia, necrotising 
enterocolitis (NEC), intestinal failure – congenital or acquired including 
short bowel syndrome – defined as bowel length of < 40 cm(20) 
Cholestatic liver disease 
Prematurity: < 37 weeks gestational age 
Other: neurodisabilities, chromosomal disorder 
Age Converted into weeks and days  
Corrected for prematurity 
Current growth Weight in kg 
Length/height in cm/m 
Head circumference in cm < 2 year of age 
Converting data to z-scores using WHO Anthro and Anthro Plus software. 
<37 weeks of gestational age, Fenton Growth calculator was used(19) 
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Malnutrition  Defined as per WHO guidelines: 
<-2 z-score moderate malnutrition 
<-2 z-score Weight for Age (21) - underweight 
<-2 z - score Weight for Height (WHZ) – wasted 
<-2 s-score Height for Age (HAZ) - stunted 
Indication for feed use Malabsorption disorder  
Diarrhoea – defined as Bristol stool chart > 6 and stoma output > 30 
ml/kg 
Gastroesophageal reflux disease – physician diagnosed 
Constipation – using criteria from the NICE guidelines 
Feed intolerance – defined as presence or worsening of 
diarrhoea/constipation and/or vomiting/ abdominal distention on 
current formula 
Conjugated jaundice 
Feed information AAF (including elemental feeds) 
EHF (including all semi-elemental feeds that are also extensively 
hydrolysed) 
Concentration of feeds: diluted, standard (as per company guidelines) or 
concentrated or ready to use nutrient-energy dense 
Route of feeding Oral 
Nasogastric feeding tube 

















Vitamin and mineral supplement 
Mineral supplement 
Omega-3 fatty acid supplementation 
Presence/ absence of 
vitamin or mineral 
deficiencies 
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Table 3: Numbers of patients contributed by individual centres 25 
Hospital Patients Number Percentage 
Brighton University Hospital NHS Trust 23 12% 
Bristol University Hospitals NHS Foundation Trust 25 13% 
King’s College Hospital NHS Foundation Trust  33 17% 
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Table 4: Pooled data of diagnostic category, stratified by use of either EHF or AAF  27 
Diagnostic Category Overall Percentage EHF AAF 
PICU ALL 31% (60/191) 36% (57/158) 9% (3/33) 
          PICU / Other 24% (45/191) 27% (42/158) 9% (3/33) 
          PICU / Cardiac 6% (11/191) 7% (11/158) 0% (0/33) 
          PICU / Prematurity 2% (4/191) 3% (4/158) 0% (0/33) 
Cancer 26% (49/191) 25% (39/158) 30% (10/33) 
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GI disease 18% (34/191) 13% (21/158) 39% (13/33) 
Liver 9% (18/191) 9% (15/158) 9% (3/33) 
Other* 6% (12/191) 6% (10/158) 6% (2/33) 
Prematurity 5% (10/191) 5% (8/158) 6% (2/33) 
Cardiac disease 4% (8/191) 5% (8/158) 0% (0/33) 
*Neurodisabilities, bone marrow transplant, High Dependency Unit, Long Term Ventilation and 1 






















Table 5: Feeding route stratified by EHF and AAF 24 
Route of Feeding 
overall 
percentage EHF AAF 
Oral 10% (20/191) 80% (16/20) 20% (4/20) 
Nasogastric tube 73% (139/191) 82% (114/139) 18% (25/139) 
Nasojejunal tube 2% (4/191) 75% (3/4) 25% (1/4) 
Percutaneous gastrostomy 14% (27/191) 89% (24/27) 11% (3/27) 
21 
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Percutaneous jejunostomy 1% (1/191) 100% (1/1) 0% (0/1) 





























Table 6: Variables significantly contribute towards the likelihood of being on either AAF or EHF 30 
Variable 
1  Variable 2 
Variable 
3 Variable 4 
Probability of being on 
an EHF expressed in % 
 
Probability of being on 
an AAF expressed in % 
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   Diarrhoea 95% 5% 
 Malabsorption   94% 6% 
  Vomiting  93% 7% 
 Malabsorption  Diarrhoea 85% 15% 
Male   Diarrhoea 84% 16% 
  Vomiting Diarrhoea 84% 16% 
Male Malabsorption   79% 21% 
 Malabsorption Vomiting  79% 21% 
Male  Vomiting  78% 22% 
 Malabsorption Vomiting Diarrhoea 60% 40% 
Male  Vomiting Diarrhoea 58% 42% 
Male Malabsorption Vomiting  50% 50% 






















Table 7: Percentage of children with growth parameters of less than -2 z-scores stratified by 22 
diagnostic category 23 
23 
This is an accepted manuscript of an article published by Wiley in Journal of Human Nutrition and 
Dietetics, available online at https://onlinelibrary.wiley.com/doi/10.1111/jhn.12794. It is not the 
copy of record. Copyright © 2020, Wiley. 
 
Diagnostic category WAZ HAZ WHZ BMI 
PICU ALL 27% 37% 11% 24% 
PICU / Cardiac 44% 55% 0% 9% 
PICU / Other 19% 31% 9% 26% 
PICU / Ex-preterm 75% 50% 50% 50% 
Cardiac disease  63% 88% 14% 25% 
GI disorders 30% 36% 13% 21% 
Cholestatic liver disease 47% 60% 21% 33% 
Cancer 11% 11% 0% 9% 
Other 33% 63% 0% 13% 
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Table 8: Vitamin and/or mineral supplementation 1 
  Overall Percentage EHF AAF 
Multivitamin 44% (84/191) 48% (76/158) 24% (8/33) 
Vitamin D 15% (28/191) 12% (19/158) 27% (9/33) 
Iron 14% (27/191) 12% (19/158) 24% (8/33) 
Multivitamin and mineral 7% (14/191) 7% (11/158) 9% (3/33) 
Calcium 1% (2/191) 1% (2/158) 0% (0/33) 
Zinc 2% (3/191) 1% (1/158) 6% (2/33) 
Probiotic 1% (1/191) 1% (1/158) 0% (0/33) 
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Table 9: Medication use stratified by EHF and AAF 3 
  Overall Percentage EHF AAF 
Proton pump inhibitor 40% (77/191) 40% (63/158) 42% (14/33) 
Anti-emetics 30% (58/191) 30% (47/158) 33% (11/33) 
Diuretics 28% (53/191) 33% (52/158) 3% (1/33) 
Chemotherapy 25% (48/191) 24% (38/158) 30% (10/33) 
Ranitidine 15% (28/191) 15% (23/158) 15% (5/33) 
Gastric Emptying Agents 15% (29/191) 13% (21/158) 24% (8/33) 
Laxatives 13% (25/191) 14% (22/158) 9% (3/33) 
Corticosteroids 8% (16/191) 9% (14/158) 6% (2/33) 
Immunomodulatory medication 7% (14/191) 6% (10/158) 12% (4/33) 
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Box 1: Key learning points for healthcare professionals 3 
 4 
• When an EHF or AAF is considered for a child that does not tolerate whole protein feeds, 
consider the reasons for the change of feed and published data specific to that condition. 
• Consider nutritional content of the feed and whether it will meet the nutritional needs for a 
child with that specific condition.  
• Children who do not tolerate standard feeds often have complex conditions that affect 
multiple organs and are on polypharmacy, which may impact on nutritional adequacy. 
• Ensure that the child on either EHF or AAF is regularly monitored for both growth and 
targeted micronutrients. 
• Audit practice of use of EHF and AAF outside of food allergy. 
• Initiate research on nutritional adequacy of use of EHF and AAF  outside of food allergy 
 
 
